我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

- u) `1 N. X7 ^7 `0 }1 L祝老马老师新年快乐！今天看了你的，《肺癌骨转移的双膦酸盐治疗》这篇文章，想有个问题请教你：我父亲由于手术前未确定病灶的良性还是恶性，所以先行手术，确定恶性后，手术后补做了骨扫描，结论：右侧股骨颈骨代谢增高灶，建议进一步检查。三个月后核磁复查：右侧髂骨、股骨头、股骨颈见结节状异常信号T1WI低信号、T2WI高信号。左侧股骨头见斑点状T2W1高信号影，髋臼及关节间隙如常，左侧髋关节囊见少量积液。结果诊断：右侧髂骨、股骨颈及两侧股骨头异常信号。问过好多医生，未能诊断是否骨转移。术后至今已7月多，一直未疼痛，碱性磷酸酶也正常，请问老师骨转移的可能性大吗？

我觉得骨转移可能性大，建议再做个核磁，看看有什么变化没有。
% X9 _+ ~1 n0 J( M  s确定后可以打骨转针。
2 U( l. g7 O3 M: Q肿瘤指标有没有检查？

谢谢马老师这么快回复;肿瘤指标有检查,CEA手术前5.6,手术后2.7,总共四次培美曲塞+顺伯,前三次后CEA都在2.7左右,第四次后4.22,现在3.6,现在跟正常人一模一样,体重回升3公斤,正常上班,真想现在的好时光能长点,再长点.

LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
: ~+ k: `' \, B# J# q. X; LTHERAPE UTIC PERSPECTIVES
( P0 h. A# o% vJ. Mazieres, S. Peters
# K5 z# P. `) d+ T' G  v8 Q4 |Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted
* D5 B+ M) U, L' }6 Atreatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
# T, E/ A5 [$ l/ [9 vtreatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
  [9 E+ J  j+ z" ddisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
2 H9 Y0 r3 R$ b7 e6 b& [22.9 months for respectively early stage and stag e IV patients.
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
" o& E  u* X9 O9 |* _reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
- p5 n% j: G4 |) E% n6 vHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
clinicaltrials.
( }# f$ S$ s( u: v( {  |

老马：你好！一口气看完你的帖子，受益非浅，现在有问题想向你请教一下
: x* p' \5 m" K   最近非常纠结于我爸爸的下一步治疗情况，想请教一下您，麻烦帮我看看他的CEA算敏感的吗？为什么最近CEA变化和肿瘤大小变化怎么不符合了呢？目前CT象征肿瘤算不算增大了呢？是否能继续空窗或者用靶向？以下是治疗帖。http://www.yuaigongwu.com/thread-8252-1-1.html
! R5 {7 q. Q. _, X* |/ Z

谢谢你这么快给我回复，骨转针已打了7针，是否要继续？
/ Y/ L/ x$ P: N. U+ r, hCEA为什么会突然变得不敏感呢？再次感谢！

) A" {) w+ x' y5 n
# O- o' L3 H0 @9 \0 |

经常上来，但是第一次注册。 父也是肺鳞癌！

向老马请教，病人的淋巴细胞亚群检测是不是很重要？

* W+ W6 a2 h5 f6 s6 h* P& d
+ L  g, f% ^( P7 l8 F: M因这个项目检查要自费
{:soso_e117:}
2 E& U' X' t9 ?5 ~) [. }所以......
下周去检查
! J6 c+ z+ a& }谢谢老马！